Stocks Health care PPBT
NASDAQ · Health carePurple Biotech Ltd. (PPBT)
It posted a net loss of $26.4M. In fiscal 2025 capital spending exceeded operating cash flow by $5.7M. At December 31, 2025 it held $8.7M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on March 19, 2026.
What Purple Biotech Ltd. does
Purple Biotech Ltd. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PPBT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$26.4M | $0.03 | -$5.7M |
| 2024 | n/a | -$7.2M | $4.99 | n/a |
| 2023 | n/a | -$19.9M | $17.96 | -$19.9M |
| 2022 | n/a | -$21.7M | $23.97 | -$16.8M |
| 2021 | n/a | $17.8M | $23.29 | -$489K |
| 2020 | $1M | $28.7M | $0.00 | $1.5M |
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Purple Biotech Ltd. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 9, 2026
- September 2, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 10, 2026
- August 7, 2026
- July 29, 2026
- June 23, 2026
- June 11, 2026
- May 20, 2026Form F-3 filing F-3
- May 15, 2026
Who owns PPBT
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Mitchell P. Kopin13G, passive with 2 related filers | 9.99% | May 13, 2026 |
Largest institutional holders
Insiders
Questions about PPBT
What does Purple Biotech Ltd. do?
Purple Biotech Ltd. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PPBT.
Is Purple Biotech Ltd. profitable?
No. In fiscal 2025 it reported a net loss of $26.4M.
When did Purple Biotech Ltd. last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on March 19, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from September 9, 2026.
Similar companies
Compare PPBT with
Follow PPBT
Get an email when Purple Biotech Ltd. files with the SEC: results, executive changes, material agreements and annual reports.
Follow PPBT: get an email when it filesWhere the numbers come from
Financial figures are the values Purple Biotech Ltd. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.